Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 6Waldenstrom Macroglobulinemia 2Recurrence 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Leukemia, B-Cell 2Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma 1Hematologic Diseases 1Chromosome 17 deletion 1

Interventions

venetoclax 6ibrutinib 4pirtobrutinib 2Sirolimus 2Rituximab 2Mycophenolic Acid 2Cyclosporine 2Cyclophosphamide 2zanubrutinib 1pembrolizumab 1loncastuximab tesirine 1fludarabine phosphate 1carfilzomib 1acalabrutinib 1Whole-Body Irradiation 1Tacrolimus 1Specimen Handling 1Rifaximin 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1Melphalan 1Magnetic Resonance Spectroscopy 1Etoposide 1Dexamethasone 1Cyclosporins 1Calcium Dobesilate 1CT-P10 1Busulfan 1Biopsy 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Waldenstrom Macroglobulinemia × pirtobrutinib × 30 days × Clear all
NCT07231952 2026-06-03

A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
40 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

NCT05734495 2026-05-28

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
46 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡